Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Eye Diseases

Infections

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Diseases and Abnormalities at or Before Birth

Rare Diseases

Carcinoma

Glioblastoma

Neuroblastoma

Sarcoma

Lung Neoplasms

Retinoblastoma

Virus Diseases

Wilms Tumor

Medulloblastoma

Sarcoma, Ewing

Carcinoid Tumor

Rhabdomyosarcoma

Rhabdomyosarcoma, Alveolar

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Soft Tissue Sarcoma

Wilms' Tumor

Ewing Sarcoma

Rhabdomyosarcoma Alveolar

Neuroendocrine Tumor

Neuroepithelioma

Dose escalation (starting at 1 × 10\^7 vp/kg), IV (in the vein) over 1 hour in a single administration

Seneca Valley Virus (biological agent)

Rudin Charles, MD, PhD

The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.

This is the first study in man of Seneca Valley Virus, a virus which seeks and kills certain tumors in non-human model systems. Subjects in this trial will be patients with advanced cancer displaying certain specified neuroendocrine features, pathologically; they will have exhausted standard methods of treatment for their tumor. The primary purpose of the trial is to determine if the virus may be administered safely. Additional purposes are to learn about the distribution of the virus in the body, the elimination of the virus from the body, the immune response to the virus and whether the virus might have some beneficial effects upon the tumors which the patients have. The first patients will be treated with low amounts of virus and subsequent patients may receive higher amounts. At the end of the trial, it is intended to select a dose for further study.

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features

Neotropix

Margaret Valnoski, President

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features	NCT00314925	Carcinoid Neuroendocrine	Seneca Valley V...	18 Years -	Neotropix
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features	NCT00314925	Carcinoid Neuroendocrine	Seneca Valley V...	18 Years -	Neotropix

Spots Global Cancer Trial Database for seneca valley virus (biological agent)